[{"orgOrder":0,"company":"Exeltis","sponsor":"IntelGenx","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2020","type":"Licensing Agreement","leadProduct":"Rizatriptan Benzoate","moa":"5-HT1D receptor","graph1":"Neurology","graph2":"Approved","graph3":"Exeltis","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Disintegrating Film","sponsorNew":"Exeltis \/ Exeltis","highestDevelopmentStatusID":"12","companyTruncated":"Exeltis \/ Exeltis"},{"orgOrder":0,"company":"Exeltis","sponsor":"Lupin Ltd","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Small molecule","year":"2022","type":"Agreement","leadProduct":"Secnidazole","moa":"DNA","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Exeltis","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Granules","sponsorNew":"Exeltis \/ Lupin Pharmaceuticals","highestDevelopmentStatusID":"12","companyTruncated":"Exeltis \/ Lupin Pharmaceuticals"},{"orgOrder":0,"company":"Exeltis","sponsor":"Luye Pharma","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2022","type":"Agreement","leadProduct":"Rivastigmine","moa":"","graph1":"Neurology","graph2":"Approved","graph3":"Exeltis","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Patch","sponsorNew":"Exeltis \/ Exeltis","highestDevelopmentStatusID":"12","companyTruncated":"Exeltis \/ Exeltis"}]

Find Clinical Drug Pipeline Developments & Deals by Exeltis

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          Pharmtech & Ingredients
                          Not Confirmed
                          Pharmtech & Ingredients
                          Not Confirmed

                          Details : Through the agreement, the company grants Exeltis exclusive rights to commercialize the Rivastigmine MD (rivastigmine), a multi-day transdermal patch for the treatment of Alzheimer’s disease.

                          Brand Name : Rivastigmine MD

                          Molecule Type : Small molecule

                          Upfront Cash : Undisclosed

                          March 31, 2022

                          Lead Product(s) : Rivastigmine

                          Therapeutic Area : Neurology

                          Highest Development Status : Approved

                          Recipient : Luye Pharma

                          Deal Size : Undisclosed

                          Deal Type : Agreement

                          blank

                          02

                          Pharmtech & Ingredients
                          Not Confirmed
                          Pharmtech & Ingredients
                          Not Confirmed

                          Details : This partnership will expand the reach of SOLOSEC®, allowing more Healthcare Providers to be aware of the benefits of SOLOSEC®, and increase access for adult women suffering with bacterial vaginosis and adults with trichomoniasis.

                          Brand Name : Solosec

                          Molecule Type : Small molecule

                          Upfront Cash : Undisclosed

                          January 27, 2022

                          Lead Product(s) : Secnidazole

                          Therapeutic Area : Infections and Infectious Diseases

                          Highest Development Status : Approved

                          Sponsor : Lupin Ltd

                          Deal Size : Undisclosed

                          Deal Type : Agreement

                          blank

                          03

                          Pharmtech & Ingredients
                          Not Confirmed
                          Pharmtech & Ingredients
                          Not Confirmed

                          Details : Under the terms of the current agreement, IntelGenx will grant Exeltis an exclusive license to manufacture and commercialize RIZAPORT® in the EU.

                          Brand Name : Rizaport

                          Molecule Type : Small molecule

                          Upfront Cash : Undisclosed

                          August 27, 2020

                          Lead Product(s) : Rizatriptan Benzoate

                          Therapeutic Area : Neurology

                          Highest Development Status : Approved

                          Recipient : IntelGenx

                          Deal Size : Undisclosed

                          Deal Type : Licensing Agreement

                          blank